Tolerability and Healthcare Utilization in Maintenance Hemodialysis Patients Undergoing Treatment for Tuberculosis-Related Conditions | Zendy

Abdurrahman Hamadah | Zendy; Lynn M. Beaulieu | Zendy; John Wilson | Zendy; Timothy R. Aksamit | Zendy; James R. Gregoire | Zendy; Amy W. Williams | Zendy; John Dillon | Zendy; Robert C. Albright | Zendy; Macaulay Onuigbo | Zendy; Venkateshwaran K. Iyer | Zendy; LaTonya J. Hickson | Zendy

Open Access

Tolerability and Healthcare Utilization in Maintenance Hemodialysis Patients Undergoing Treatment for Tuberculosis-Related Conditions

Author(s) -

Abdurrahman Hamadah,

Lynn M. Beaulieu,

John Wilson,

Timothy R. Aksamit,

James R. Gregoire,

Amy W. Williams,

John Dillon,

Robert C. Albright,

Macaulay Onuigbo,

Venkateshwaran K. Iyer,

LaTonya J. Hickson

Publication year - 2016

Publication title -

the nephron journals/nephron journals

Language(s) - English

Resource type - Journals

eISSN - 2235-3186

pISSN - 1660-8151

DOI - 10.1159/000444148

Subject(s) - medicine , tolerability , hemodialysis , intensive care medicine , tuberculosis , health care , disease , adverse effect , pathology , economics , economic growth

The incidence of tuberculosis (TB) in end-stage renal disease is significantly higher than that in the general population. Among those with kidney dysfunction, anti-TB treatment is associated with increased side effects, but the effect on healthcare utilization is unknown. Methods/Aim: To assess patient-reported symptoms, adverse effects and describe changes in healthcare utilization patterns during treatment for TB, we conducted a case series (n = 12) of patients receiving maintenance hemodialysis (HD) from Mayo Clinic Dialysis Services and concurrent drug therapy for TB from January 2002 through May 2014. Healthcare utilization (hospitalizations and emergency department (ED) visits independent of hospital admission) was compared before and during treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research